The Size of the Asia Pacific Renal Biomarkers Market was worth USD 247.08 million in 2021 and estimated to grow at a CAGR of 9.24%, to reach USD 384.42 million by 2026 during the forecast period 2021 to 2026.
A Renal Biomarkers indicates the presence of kidney diseases by measuring blood or urine levels. Kidney diseases are one of the main reasons for death around the world. The incidence of Chronic kidney diseases have increased due to factors like diabetes and hypertension. Advancements in technology have led to the introduction of renal biomarker which detects kidney problems accurately.
The significant drivers are rising population with kidney problems, growing incidence of renal diseases, increasing geriatric population and increasing incidence of diseases like high blood pressure and diabetes. Advancements in technology is also expected to drive the market over the forecast period. Reimbursement issues are major restraints limiting this industry.
This research report on the Asia Pacific Renal Biomarkers Market has been segmented and sub-segmented into the following categories
By Diagnostic Technique:
By Type:
By Country:
Top Companies dominating the Asia Pacific Renal Biomarkers Market Profiled in the Report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Technique
5.1.1 Introduction
5.1.2 Chemiluminescent Enzyme Immunoassay
5.1.3 Colorimetric Assay
5.1.4 Enzyme-Linked Immunosorbent Assay
5.1.5 Liquid Chromatography-Mass Spectrometry
5.1.6 Particle-Enhanced Turbidimetric Immunoassay
5.1.7 Y-o-Y Growth Analysis, By Diagnostic Technique
5.1.8 Market Attractiveness Analysis, By Diagnostic Technique
5.1.9 Market Share Analysis, By Diagnostic Technique
5.2 Type
5.2.1 Introduction
5.2.2 Up-Regulated Proteins
5.2.2.1 Interleukin 18
5.2.2.2 Kidney injury molecule 1
5.2.2.3 Neutrophil gelatinase-associated lipocalin
5.2.3 Functional Biomarker
5.2.3.1 Serum Creatinine
5.2.3.2 Serum Cystatin C
5.2.3.3 Urine Albumin
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 End User
5.3.1 Introduction
5.3.2 Diagnostic Labs
5.3.3 Hospitals
5.3.4 Outpatient Clinics
5.3.5 Research Centres
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Technique
6.1.3.3 By Type
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Technique
6.1.4.3 By Type
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Technique
6.1.5.3 By Type
6.1.5.4 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
6.7 Rest of APAC
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Beckman Coulter, Inc.
8.4 Randox Laboratories Ltd
8.5 Astute Medical Inc.
8.6 F. Hoffmann-La Roche AG
8.7 Siemens Healthcare Diagnostics Inc.
8.8 Alere Inc.
8.9 bioMérieux SA
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
